{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"10"}]}],"title":"At least one TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"5"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically relevant changes in laboratory tests, physical examination, electrocardiogram, and vital signs","groups":[{"description":"Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG000","title":"Cohort 1: ENKTL"},{"description":"Participants with other R/R mature T-cell neoplasms \\[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG001","title":"Cohort 2: PTCL-NOS, AITL, and ALCL"},{"description":"Participants with R/R cutaneous T-cell lymphoma \\[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG002","title":"Cohort 3: MF and SS"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set includes all participants who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 1 week","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}